The target of a ‘criminal’ critique quietly confirmed some doubts
Earlier this month, when an anonymous short report about Applied Therapeutics circulated around the Internet, the company denounced it as “criminal activity” and demanded its author be prosecuted. Then, a week later, the company quietly edited its investor materials, lending weight to the author’s critique.
As STAT’s Adam Feuerstein reports, it all stems from the company’s lead drug, AT-007, in development to treat an ultra-rare disorder. The anonymous report pointed out graphs, previously presented by Applied Therapeutics, that appeared inconsistent. Those graphs got amended a week later in a presentation posted to the company’s website, something Applied Therapeutics didn’t disclose.
Company CEO Shoshana Shendelman declined to be interviewed about the edited presentation. She also sold $1.4 million in company stock in the days before the amended graphs were made public.
Read more.
As STAT’s Adam Feuerstein reports, it all stems from the company’s lead drug, AT-007, in development to treat an ultra-rare disorder. The anonymous report pointed out graphs, previously presented by Applied Therapeutics, that appeared inconsistent. Those graphs got amended a week later in a presentation posted to the company’s website, something Applied Therapeutics didn’t disclose.
Company CEO Shoshana Shendelman declined to be interviewed about the edited presentation. She also sold $1.4 million in company stock in the days before the amended graphs were made public.
Read more.
No hay comentarios:
Publicar un comentario